Conference abstractPublished 2021
Apixaban in elderly patients with atrial fibrillation and renal dysfunction: findings from a national registry
Beilinson Hospital, Rabin Medical Center, Israel
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: We aimed to evaluate the clinical characteristics and outcomes of patients 75 years and older with atrial fibrillation (AF) and renal dysfunction who are treated with apixaban. Methods: A sub analysis of a multicenter prospective cohort registry, where consecutive eligible apixaban or warfarin treated patients with non-valvular AF and renal impairment (eGFR MDRD < 60 ml/min/BSA) were registered. All patients were prospectively followed-up for clinical events and dosing adjustments over a mean period of 1 year. The current sub analysis focused on the subjects aged ≥75 years. The primary outcomes were 1 year: mortality, stroke or systemic embolism, major bleeding and myocardial infarction as well as their composite occurrence. Results: In the subjects 75 years or older with renal impairment (n = 1460), the use of apixaban 5 mg was associated with improved 1-year survival rate (7.1% compared to 16.5% in the apixaban 2.5 mg group and 18.4% in the warfarin group; log rank p<0.001). Also, 5 mg apixaban showed lower risk of 1-year composite endpoint compared to apixaban 2.5 mg and warfarin (9.2% vs. 19.6% and 20.6%, respectively; log rank p<0.001). Further analysis on 1:1 matched data revealed a distinct advantage of efficacy to apixaban 2.5 mg appropriate dose reduction vs. warfarin. Never the less, similar safety profiles were observed. Conclusion: Appropriate dose apixaban is a considerable alternative to warfarin in older adults with concurrent renal impairment for stroke prevention in the setting of AF. Key Words: Atrial Fibrillation; Apixaban; Warfarin; older adults; Stroke
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Aging and Geriatric Medicine
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Ela Giladi”
